All In Biotech

Drug Trial Radar · NCT03158532

Prevention of Radial Artery Occlusion After Transradial Access Using Nitroglycerin

Last checked: Nov 19, 2026Latest source record: Dec 9, 2024 (this record)Source: ClinicalTrials.govMethods & limitations

CompletedResults posted on the registryPivotal-lookingPhase 3. Randomized with 2,040 participants. This is a heuristic, not a regulatory label.

Status

Completed

Enrollment

2,040

Actual

Start

Jul 6, 2017

Primary completion

Oct 1, 2021

Study completion Nov 1, 2021

Sponsor

Lead sponsor
Instituto de Cardiologia de Santa CatarinaAcademic, hospital or other
Sponsor type
Academic, hospital or other
First posted
May 18, 2017

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 3
Allocation
Randomized
Model
Factorial
Masking
Quadruple (participant, care provider, investigator, outcomes assessor)
Primary purpose
Prevention
FDA-regulated drug
No
Who can join
All sexes, from 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

The radial approach for a coronary angiography has became popular in several centers because of its simplicity and fewer complications. The radial artery occlusion (RAO) is the main inconvenient and impose a limitation of future use of the radial artery as an access site for catheterization in the future. Several strategies have been used to decrease the incidence of RAO (heparin, patent hemostasis, etc). Nitrates in intra-arterial have been widely studied in prevention of this spasm. Current data show that nitroglycerin intra-arterial at the end of the procedure reduce the incidence of RAO. The hypothesis that use of nitroglycerin at the start of catheterization would have the same effect was not tested.

Conditions

  • Injury of Radial Artery

Interventions

  • Nitroglycerin IDrug

    500 microgram of Nitroglycerin intra-arterially administered through the radial sheath, right after sheath placement and before catheterization.

  • Placebo IDrug

    Saline 0,9% intra-arterially administered through the radial sheath, right after sheath placement and before catheterization.

  • Nitroglycerin IIDrug

    500 microgram of Nitroglycerin intra-arterially administered through the radial sheath, just before sheath removal and before hemostasis.

  • Placebo IIDrug

    Saline 0,9% intra-arterially administered through the radial sheath, just before sheath removal and before hemostasis.

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Radial Artery OcclusionTime frame: 2 to 24 hours after procedure

Locations

3 sites in 1 country. Site status is shown where the registry gives one.

  • Hospital Universitário Professor Polydoro Ernani de São Thiago

    Florianópolis, Santa Catarina, Brazil

  • Instituto de Cardiologia de Santa Catarina

    São Jose, Santa Catarina, Brazil

  • Irmandade Santa Casa Misericórdia Marília

    Marília, São Paulo, Brazil

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.